EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 24th, 2021 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AGREEMENT is entered into as of November 24, 2021 (“Effective Date”), by and between iX Biopharma Europe Limited, a private company formed under the laws of Ireland with a place of business at 32 Merrion Street Upper, Dublin 2, Dublin, D02KW80, Ireland (“Licensor”) and Seelos Therapeutics, Inc., a corporation organized under the laws of Nevada with a place of business at 300 Park Avenue, 12th Floor, New York, NY (“Licensee”) (this “Agreement”). Licensor and Licensee are each sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
SEELOS THERAPEUTICS, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • November 24th, 2021 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York
This Common Stock Purchase Agreement (this “Agreement”) is made and entered into as of November 24, 2021, by and between Seelos Therapeutics, Inc., a corporation organized under the laws of the State of Nevada, U.S.A. (the “Company”), and iX Biopharma Europe Limited, a private company formed under the laws of Ireland (the “Purchaser”).
